Genedrive Plc Doubles Annual Revenue to £1m and Eyes Growth from NHS Reforms

Right, let’s cut through the noise on this Genedrive update. Doubling annual revenue? From half a million quid to a cool million? Not bad for a Monday, even if the absolute numbers are still firmly in the ‘growth phase’ territory. But as always with these AIM-listed medtechs, it’s the trajectory and the catalysts that get the pulse racing. This RNS is packed with more forward momentum than we’ve seen from Genedrive in a while.

The Headline Grab: Revenue Doubles, Momentum Builds

Genedrive expects to report total income of approximately £1 million for FY25 (ended June 2025). That’s double the £0.5m achieved in FY24 (which itself was a massive leap from the £60k in FY23). Crucially, the growth accelerated significantly in the second half:

• H1 FY25: £0.35m
• H2 FY25: £0.65m

That H2 surge suggests sales momentum is genuinely building. Overheads were held steady year-on-year, with spending strategically shifted towards commercial activities – a sensible move when you’re starting to gain traction.

FY26: Visibility & Catalysts Galore

This is where it gets interesting. Genedrive isn’t just hoping for growth; they already have tangible visibility for the *current* financial year (FY26, started July 2025):

• £0.6m of expected income already in sight by the end of August (month two of FY26).

This early visibility stems from several near-term catalysts:

Domestic Drivers (UK NHS)

• NICE Evidence Submission: Completing and submitting evidence for their NICE Early Value Assessment (EVA) is expected to be a major catalyst for wider UK adoption of their tests.
• Scotland Rollout: Phased national implementation of the MT-RNR1 ID Kit (for antibiotic-induced hearing loss risk in neonates) and the CYP2C19 point-of-care pilot (for stroke medication response) are slated to commence around October 2025.
• Manchester Programme: A 12-month Acute Coronary Syndrome programme using the CYP2C19 rapid test kicks off at Manchester University NHS Foundation Trust.

International Expansion Gaining Traction

While the NHS is foundational, Genedrive wisely isn’t putting all its eggs in one (often slow-paying) basket:

• Europe & Middle East: The RNS specifically mentions “initial operational and commercial traction” in Italy, the Netherlands, UAE, Bahrain, Kuwait, Saudi Arabia, and Qatar. Preliminary sales of *both* flagship products are happening.
• The US Market – The Big Prize:
  • MT-RNR1 ID Kit: Progressing under the FDA’s Breakthrough Device designation.
  • CYP2C19 ID Kit: Targeting an FDA 510(k) submission in early 2026, with a potential 3-4 month review window. This is a concrete, near-term regulatory milestone for a significant market.

The clear message: FY26 revenues are expected to grow further as international activities accelerate.

The NHS Reforms: A Potential Game-Changer

Genedrive isn’t just passively hoping for NHS uptake; they’re strategically positioned to capitalise on major structural changes:

• The UK Government’s 10-Year Health Plan explicitly prioritises HealthTech and MedTech.
• A critical gap is being addressed: No national funding pathway for NICE-recommended MedTech diagnostics (unlike medicines).
• NICE’s technology appraisal pathway is being expanded to cover diagnostics, with mandated NHS funding expected to be in place by April 2026.
• Adoption of innovation will become a key performance criterion for NHS providers/commissioners.
• A new ‘innovator passport’ will aim to streamline the rollout of proven tech across NHS trusts.

CEO Gino Miele rightly highlights the significance: “…our best-in-class CE-IVD certified, NICE-recommended rapid near patient genetic testing platform… represent novel solutions to clinical issues of global relevance. Our domestic revenue ramp is intrinsically linked to an increase in better patient outcomes and the realisation of cost savings to the NHS and ultimately the UK taxpayer.” He also notes the government’s shift towards prevention aligns perfectly with Genedrive’s portfolio.

The Products: Why They Matter

Let’s not forget the tech driving this:

• Genedrive® MT-RNR1 ID Kit: Rapid (26 min) point-of-care test for neonates to prevent antibiotic-induced hearing loss. A world-first, NICE recommended.
• Genedrive® CYP2C19 ID Kit: Rapid (70 min) test to identify stroke patients unlikely to respond to Clopidogrel, enabling faster, more effective treatment. NICE recommended, no direct competitor at point-of-care.
• Key Advantages: Simple, near-patient use, ambient temperature stable (no cold chain), single-use cartridges.

These address real, time-critical clinical decisions, improving outcomes *and* saving system costs – the holy grail for adoption.

The Elephant in the Room: Cash

The RNS ends with the practical reality: cash balances circa £700k. Let’s be blunt: that’s tight for a company with this level of commercial and regulatory activity. The Board states they are “actively assessing a broad range of financing options” for additional working capital. Expect a fundraise announcement sooner rather than later – it’s a necessary step to fuel the growth trajectory they’re outlining.

The Takeaway: Building Momentum, Catalysts Loom

Genedrive’s update is one of their most positive in recent times. Doubling revenue (even off a low base) is solid progress, but the real story is the acceleration in H2 and the significant visibility/catalysts for FY26. The combination of:

• Imminent NHS rollouts (Scotland, Manchester),
• The transformative potential of mandated NHS funding for NICE-recommended diagnostics from April 2026,
• Growing international traction, and
• Concrete US regulatory milestones (especially the CYP2C19 510(k) submission early next year)

…paints a picture of a company hitting an inflection point. The financing need is clear and present, but if executed well, it could be the fuel that propels Genedrive from promising innovator towards a commercially sustainable player in the rapidly evolving point-of-care diagnostics market. One to watch closely as these catalysts unfold over the next 12-18 months.